These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9420657)

  • 41. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
    Reis SE; Holubkov R; Young JB; White BG; Cohn JN; Feldman AM
    J Am Coll Cardiol; 2000 Aug; 36(2):529-33. PubMed ID: 10933368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).
    Deswal A; Petersen NJ; Feldman AM; Young JB; White BG; Mann DL
    Circulation; 2001 Apr; 103(16):2055-9. PubMed ID: 11319194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential response to vesnarinone by cardiac fibroblasts isolated from normal and aortic regurgitant hearts.
    Ross JS; Goldfine SM; Herrold EM; Borer JS
    Am J Ther; 1998 Nov; 5(6):369-75. PubMed ID: 10099079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity.
    Inoue M; Kim BH; Hori M; Tsuneoka Y; Matsubara N; Kamada T; Kodama K; Naka M; Nanto S; Higashino Y
    Heart Vessels; 1986; 2(3):166-71. PubMed ID: 3793669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New medical therapies for advanced left ventricular dysfunction.
    Baughman K
    Cardiol Clin; 1995 Feb; 13(1):27-34. PubMed ID: 7796429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
    Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
    J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart.
    Kitakaze M; Minamino T; Funaya H; Node K; Shinozaki Y; Mori H; Hori M
    Circulation; 1997 Apr; 95(8):2108-14. PubMed ID: 9133521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line.
    Shioi T; Matsumori A; Matsui S; Sasayama S
    Life Sci; 1994; 54(1):PL11-6. PubMed ID: 8255163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. OPC-8212 in the treatment of congestive heart failure: results of a pilot study.
    Kubo SH; Rector TS; Strobeck JE; Cohn JN
    Cardiovasc Drugs Ther; 1988 Dec; 2(5):653-60. PubMed ID: 3154640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
    Chatterjee K; De Marco T
    Med Clin North Am; 2003 Mar; 87(2):391-418. PubMed ID: 12693731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
    LeJemtel TH
    Curr Cardiol Rep; 1999 May; 1(1):31. PubMed ID: 10980817
    [No Abstract]   [Full Text] [Related]  

  • 53. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
    [No Abstract]   [Full Text] [Related]  

  • 55. New therapeutic targets for the development of positive inotropic agents.
    Tamargo J; Duarte J; Caballero R; Delpón E
    Discov Med; 2011 Nov; 12(66):381-92. PubMed ID: 22127109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Inotropic effect of novel domestic cardiotonic agent, vesnarinone--test in vitro].
    Han W; Qin Y; Zhang Z; Zhou S; Yang Z
    Hua Xi Yi Ke Da Xue Xue Bao; 1994 Sep; 25(3):316-20. PubMed ID: 7896252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New positive inotropic agents in the treatment of left ventricular dysfunction.
    De Luca L; Proietti P; Palombaro GL; Battagliese A; Celotto A; Bucciarelli Ducci C; Fedele F
    Ital Heart J; 2004 Jun; 5 Suppl 6():63S-67S. PubMed ID: 15185917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The search for the ideal positive inotropic agent.
    Packer M
    N Engl J Med; 1993 Jul; 329(3):201-2. PubMed ID: 8515793
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical overview of the novel inotropic agent toborinone.
    MacGowan GA
    Expert Opin Investig Drugs; 2000 May; 9(5):1109-17. PubMed ID: 11060731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.